Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of Nafamostat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 known ✓ | P00734 | 5/20 | 0.86 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.86 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.86 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.86 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.86 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.86 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.86 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.86 |
| ▸ | HTR3A known ✓ | P46098 | 1/20 | 0.86 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.86 |
| ▸ | GHSR known ✓ | Q92847 | 1/20 | 0.86 |
| ▸ | FTO | Q9C0B1 | 1/20 | 1.00 |
| ▸ | PRSS1 | P07477 | 12/20 | 0.86 |
| ▸ | HGFAC | Q04756 | 4/20 | 0.86 |
| ▸ | KLK1 | P06870 | 3/20 | 0.86 |
| ▸ | C1R | P00736 | 2/20 | 0.86 |
| ▸ | F10 | P00742 | 2/20 | 0.86 |
| ▸ | PLG | P00747 | 2/20 | 0.86 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.86 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nafamostat SCHEMBL25197320 | 1.00 | FTO (1.00) | FTOPRSS1F2HGFACKLK1 | |
| Nafamostat SCHEMBL135504 | 0.93 | PRSS1 (1.00) | FTOPRSS1F2HGFACKLK1 | |
| Nafamostat SCHEMBL29360143 | 0.93 | PRSS1 (1.00) | FTOPRSS1F2HGFACKLK1 | |
| Nafamostat SCHEMBL29358879 | 0.93 | PRSS1 (1.00) | FTOPRSS1F2HGFACKLK1 | |
| SCHEMBL10922456 | 0.85 | FTO (0.74) | FTOPRSS1F2HGFACKLK1 | |
| SCHEMBL7340875 | 0.85 | FTO (0.74) | FTOPRSS1F2HGFACKLK1 | |
| SCHEMBL25633204 | 0.85 | PRSS1 (0.76) | FTOPRSS1F2HGFACKLK1 | |
| Sepimostat SCHEMBL16617107 | 0.83 | FTO (0.70) | FTOPRSS1F2HGFACKLK1 | |
| SCHEMBL7347942 | 0.82 | FTO (0.70) | FTOPRSS1F2HGFACKLK1 | |
| Nafamostat SCHEMBL564665 | 0.82 | FTO (0.70) | FTOPRSS1F2HGFACKLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119504499-A | Synthesis method of 6-amidino-2-naphthol mesylate | 江苏杜瑞制药有限公司 | 2025-02-25 | — | — | CN | disclosed |
| CN-119492835-A | Liquid phase detection method for nafamostat mesylate related substances | 华仁药业（日照）有限公司 | 2025-02-21 | — | — | CN | disclosed |
| CN-115192537-B | Nafamostat mesylate composition and preparation method thereof | 康普药业股份有限公司 | 2024-03-26 | — | — | CN | disclosed |
| CN-115192537-A | Nafamostat mesylate composition and preparation method thereof | 康普药业股份有限公司 | 2022-10-18 | — | — | CN | disclosed |
| US-20220227884-A1 | COMPLEMENT INHIBITION FOR IMPROVED NERVE REGENERATION | REGENESANCE B.V. (NL) | 2022-07-21 | — | — | US | disclosed |
| WO-2021215798-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING SARS-CORONAVIRUS INFECTION, AND MEDICAL USE THEREOF | 재단법인 한국파스퇴르연구소 (KR) | 2021-10-28 | — | — | WO | disclosed |
| CN-111821292-A | Application method of nafamostat mesylate in treatment of chlamydia genital tract infection | 中南大学湘雅二医院 | 2020-10-27 | — | — | CN | disclosed |
| CN-104208057-B | Nafamostat Mesilate is preparing the application in preventing nervous system disease agent | 江苏杜瑞制药有限公司 | 2018-07-17 | — | — | CN | disclosed |
| CN-103641749-B | A kind of preparation method of nafamostat mesylate | SHANDONG YONGTAI CHEMICAL Co.,Ltd. (CN) | 2016-02-10 | — | — | CN | disclosed |
| CN-103641749-A | Preparation method of nafamostat mesylate | SHANDONG YONGTAI CHEMICAL CO | 2014-03-19 | — | — | CN | disclosed |
| CN-102871998-A | Application of nafamostat mesilate in preparing drugs for preventing and curing ischemic cerebral apoplexy | JIANGSU DURUI PHARMACEUTICAL CO LTD | 2013-01-16 | — | — | CN | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| US-20090005321-A1 | Phenylazetidinone Derivatives | MICROBIA, INC. (US) | 2009-01-01 | — | — | US | disclosed |
| US-20080194494-A1 | 4-Biarylyl-1-Phenylazetidin-2-One Glucuronide Derivatives for Hypercholesterolemia | MICROBIA, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| EP-1879860-A2 | 1,4-DIPHENYL-3-HYDROXYALKYL-2-AZETIDINONE DERIVATIVES FOR TREATING HYPERCHOLESTROLEMIA | Microbia Inc. (US) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006122186-A2 | 1,4-DIPHENYL-3-HYDROXYALKYL-2-AZETIDINONE DERIVATIVES FOR TREATING HYPERCHOLESTROLEMIA | MICROBIA, INC. (US) | 2006-11-16 | — | — | WO | disclosed |
| CN-1658903-A | Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications | SCHERING CORP (US) | 2005-08-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194494-A1 | 4-Biarylyl-1-Phenylazetidin-2-One Glucuronide Derivatives for Hypercholesterolemia | CYP46A1, CYP7A1, UGT1A1 | F2 1125/4885CHRM1 4562/4885DRD2 1901/4885 |
| US-20090005321-A1 | Phenylazetidinone Derivatives | TYR, AAAS, FANCD2 | F2 2908/4885CHRM1 4286/4885DRD2 342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.